Duration of immunity (DOI)--The regulatory issues

Area of Science:

• Veterinary immunology
• Comparative immunology
• Regulatory science

Background:

• The efficacy of vaccines, particularly duration of immunity (DOI), is crucial for companion animal health.
• Regulatory requirements for vaccine DOI vary significantly between major markets like the European Union (EU) and the United States (US).
• Current regulatory frameworks impact vaccine development, labeling, and the data required to support efficacy claims.

Purpose of the Study:

• To compare and contrast the regulatory approaches to vaccine duration of immunity for cats and dogs in the EU and US.
• To analyze the implications of these differing regulatory requirements on vaccine efficacy claims and data generation.
• To discuss the advantages and disadvantages of various methods for determining vaccine DOI, including laboratory and field studies.

Main Methods:

• Comparative analysis of EU and US regulatory guidelines for veterinary vaccines.
• Review of scientific literature and industry practices regarding duration of immunity studies.
• Discussion of methodologies for assessing vaccine efficacy, such as challenge studies, field trials, and surrogate markers.
• Comparison of approaches in small animal vaccines versus human medicine.

Main Results:

• The EU mandates product-specific DOI data supported by rigorous trials, often resulting in minimum DOI claims due to cost and welfare concerns.
• The US traditionally has not required product-specific DOI for most vaccines, relying instead on disease-specific guidelines from scientific authorities.
• Both regions are moving towards greater transparency, with potential indications of data limitations on labels and requirements for extended DOI claims.

Conclusions:

• Divergent regulatory landscapes influence the data available for companion animal vaccines, impacting product claims and accessibility.
• The focus on individual protection in small animal vaccines, unlike population-level protection in some other species, presents unique challenges.
• Ongoing regulatory evolution aims to improve the scientific basis for vaccine DOI claims, balancing efficacy, cost, and animal welfare.